(NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates ... His leadership will strengthen our capabilities and accelerate our ...

Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...

Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition - - Continued to advance three clinical programs ...

This advertisement has not loaded yet, but your article continues below. Air defense forces destroyed more than 140 targets, President Volodymyr Zelenskyy said, adding that Ukrainian F-16 pilots ...